Tolerability Study of Xerecept® in Pediatric Patients

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: braintumormetastaticbreasttumors
  Phrases that lowered it: tolerabilityevaluate theto evaluatethe safetyat screening
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 7.4% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 3 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Maximum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 74.1% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 4 (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 1 (lowers risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE) NCT00691522 · started 2008 · scored riskier than 78% of active trials terminated
• Low Dose Versus Usual Dose Dexamethasone for Symptom Control in Children Undergoing Cranial or Craniospinal Radiation NCT01135550 · started 2010 · scored riskier than 26% of active trials terminated
• A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) NCT00960063 · started 2009 · scored riskier than 58% of active trials terminated
• Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors NCT01259479 · started 2010 · scored riskier than 64% of active trials completed
• RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors NCT04525014 · started 2023 · scored riskier than 86% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.